Naltrexone-Acetaminophen Combination
Acute Migraine
Key Facts
About Allodynic Therapeutics
Allodynic Therapeutics is pioneering a non-opioid approach to treating neuropathic pain and migraine with its naltrexone-acetaminophen combination. The company has generated promising data from four investigator-initiated Phase 2 trials and is advancing into a formal Phase 2 study for acute migraine. By targeting the Toll-Like Receptor 4 (TLR4) and COX-2 pathways, the combination aims to address a significant unmet need in pain management, potentially offering a safer alternative to opioids and tapping into a large market of millions of patients in the U.S.
View full company profileAbout Allodynic Therapeutics
Allodynic Therapeutics is pioneering a non-opioid approach to treating neuropathic pain and migraine with its naltrexone-acetaminophen combination. The company has generated promising data from four investigator-initiated Phase 2 trials and is advancing into a formal Phase 2 study for acute migraine. By targeting the Toll-Like Receptor 4 (TLR4) and COX-2 pathways, the combination aims to address a significant unmet need in pain management, potentially offering a safer alternative to opioids and tapping into a large market of millions of patients in the U.S.
View full company profileAbout Allodynic Therapeutics
Allodynic Therapeutics is pioneering a non-opioid approach to treating neuropathic pain and migraine with its naltrexone-acetaminophen combination. The company has generated promising data from four investigator-initiated Phase 2 trials and is advancing into a formal Phase 2 study for acute migraine. By targeting the Toll-Like Receptor 4 (TLR4) and COX-2 pathways, the combination aims to address a significant unmet need in pain management, potentially offering a safer alternative to opioids and tapping into a large market of millions of patients in the U.S.
View full company profileTherapeutic Areas
Other Acute Migraine Drugs
| Drug | Company | Phase |
|---|---|---|
| PUR3100 | Pulmatrix | Phase 2 |
| TRV250 | Trevena | Phase 1 |
| ELYXYB® | SCILEX | Marketed |
| Elyxyb® (celecoxib oral solution) | Scilex Holding | Commercial |